The future of targeted therapies for brain metastases

被引：4

作者：

Berghoff, Anna S. ^{[1
,2
]}

Preusser, Matthias ^{[1
,2
]}

机构：

[1] Med Univ Vienna, Div Clin Oncol, Ctr Comprehens Canc, Dept Med 1,Cent Nervous Syst Unit CCC CNS, Vienna, Austria

[2] Med Univ Vienna, CNS Tumors Unit, Ctr Comprehens Canc, Vienna, Austria

来源：

FUTURE ONCOLOGY | 2015年 / 11卷 / 16期

关键词：

ALK translocation; anti-HER2; therapy; brain metastases; EGFR mutation; targeted therapies; CELL LUNG-CANCER; NERVOUS-SYSTEM METASTASES; LAPATINIB PLUS CAPECITABINE; TUMOR BARRIER PERMEABILITY; TYROSINE KINASE INHIBITORS; PHASE-II TRIAL; BREAST-CANCER; OPEN-LABEL; TRASTUZUMAB EMTANSINE; CNS METASTASES;

D O I：

10.2217/fon.15.127

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Brain metastases (BM) are an increasing challenge in the management of patients with advanced cancer. Treatment options for BM are limited and mainly focus on the application of local therapies. Systemic therapies including targeted therapies are only poorly investigated, as patients with BM were frequently excluded from clinical trials. Several targeted therapies have shown promising activity in patients with BM. In the present review we discuss existing and emerging targeted therapies for the most frequent BM primary tumor types. We focus on challenges in the conduction of clinical trials on targeted therapies in BM patients such as patient selection, combination with radiotherapy, the obstacles of the blood-brain barrier and the definition of study end points.

引用

页码：2315 / 2327

页数：13

共 108 条

[1]

[Anonymous], ANN ONCOL

[2]

[Anonymous], 2014, J CLIN ONCOL S

[3] Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype [J].

Arvold, Nils D. ;

Oh, Kevin S. ;

Niemierko, Andrzej ;

Taghian, Alphonse G. ;

Lin, Nancy U. ;

Abi-Raad, Rita F. ;

Sreedhara, Meera ;

Harris, Jay R. ;

Alexander, Brian M. .

BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (01) :153-160

[4] Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study [J].

Bachelot, Thomas ;

Romieu, Gilles ;

Campone, Mario ;

Dieras, Veronique ;

Cropet, Claire ;

Dalenc, Florence ;

Jimenez, Marta ;

Le Rhun, Emilie ;

Pierga, Jean-Yves ;

Goncalves, Anthony ;

Leheurteur, Marianne ;

Domont, Julien ;

Gutierrez, Maya ;

Cure, Herve ;

Ferrero, Jean-Marc ;

Labbe-Devilliers, Catherine .

LANCET ONCOLOGY, 2013, 14 (01) :64-71

[5] Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system [J].

Barnholtz-Sloan, JS ;

Sloan, AE ;

Davis, FG ;

Vigneau, FD ;

Lai, P ;

Sawaya, RE .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :2865-2872

[6] Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases [J].

Bartsch, R. ;

Berghoff, A. ;

Pluschnig, U. ;

Bago-Horvath, Z. ;

Dubsky, P. ;

Rottenfusser, A. ;

DeVries, C. ;

Rudas, M. ;

Fitzal, F. ;

Dieckmann, K. ;

Mader, R. M. ;

Gnant, M. ;

Zielinski, C. C. ;

Steger, G. G. .

BRITISH JOURNAL OF CANCER, 2012, 106 (01) :25-31

[7] Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer [J].

Bartsch, Rupert ;

Rottenfusser, Andrea ;

Wenzel, Catharina ;

Dieckmann, Karin ;

Pluschnig, Ursula ;

Altorjai, Gabriela ;

Rudas, Margaretha ;

Mader, Robert M. ;

Poetter, Richard ;

Zielinski, Christoph C. ;

Steger, Guenther G. .

JOURNAL OF NEURO-ONCOLOGY, 2007, 85 (03) :311-317

[8] Breast cancer brain metastases responding to primary systemic therapy with T-DM1 [J].

Bartsch, Rupert ;

Berghoff, Anna S. ;

Preusser, Matthias .

JOURNAL OF NEURO-ONCOLOGY, 2014, 116 (01) :205-206

[9] Optimal Management of Brain Metastases from Breast Cancer Issues and Considerations [J].

Bartsch, Rupert ;

Berghoff, Anna S. ;

Preusser, Matthias .

CNS DRUGS, 2013, 27 (02) :121-134

[10] What is the blood-brain barrier (not)? [J].

Bechmann, Ingo ;

Galea, Ian ;

Perry, V. Hugh .

TRENDS IN IMMUNOLOGY, 2007, 28 (01) :5-11

← 1 2 3 4 5 6 7 8 9 10 →